Compare Charles River Laboratories Intl. Inc (CRL) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Direxion Daily S&P 500 Bull 3X Shares trades at $297.97 (market cap $7.36B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Direxion Daily S&P 500 Bull 3X Shares is more actively traded (1,835,467 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| CRL | SPXL | |
|---|---|---|
Market Cap | $14.23B | $7.36B |
Volume | 1,176,885 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $310.77 | $301.38 |
52-Week Low | $149.93 | $170.20 |
Typical Hold Time | 33 Days | 32 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
SPXL trades at $297.97, up 0.38% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 66.91 suggesting mild overbought conditions. Support levels begin at $289 with resistance at $297. Recent news highlights S&P 500 valuation debates and profit growth expectations shifting from 35% in 2026 to 15% in 2027.
Outlook remains cautiously optimistic given the ETF's leveraged exposure to S&P 500 momentum. Key risks include market concentration in top holdings and potential profit growth deceleration. The technical setup favors continued upside if $297 resistance breaks, while failure to hold $289 support could signal near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
